Union Health Minister, Dr Mansukh Mandaviya, said a nasal vaccine against Covid-19, developed by Bharat Biotech, has been approved by the department of drug control, to “limit its use” use” in adults “in an emergency situation,” said Union Health Minister Dr Mansukh Mandaviya.
Big boost for India’s fight against COVID-19!
Bharat Biotech’s ChAd36-SARS-CoV-S COVID-19 (Chimpanzee Adenovirus Vectored) recombinant vaccine has been approved by @CDSCO_INDIA_INF for primary immunization against COVID-19 in the 18+ age group to limit emergency use.
– Dr. Mansukh Mandaviya (@mansukhmandviya) September 6, 2022
“India has harnessed science, research and development, and human resources … under the leadership of Prime Minister Narendra Modi,” the minister said.
In February, in the country’s first anti-Covid drug, Mumbai-based Glenmark launched a nasal spray (branded as FabiSpray) in partnership with SaNOizing, to treat adult patients.
The company has received manufacturing and marketing approval from India’s Directorate of Drug Control for Nitric Oxide Nasal Spray as part of its expedited approval process. “The Phase 3 trial in India met the critical criteria and demonstrated a 94% reduction in viral load in 24 hours and 99% in 48 hours,” the official statement said.
As for the pandemic status today, India has seen a one-day increase of 4,417 coronavirus infections, the lowest level in three months, according to government data updated at 8am on Tuesday.
Active Covid cases have dropped to 52,336, while 23 deaths have been reported.
Active cases now account for 0.12% of total infections while the recovery rate has risen to 98.69%, the Health Ministry said.
Vaccine development is also being accelerated worldwide. UK health authorities on Saturday approved a second “bivalent” vaccine to be used as a booster to target both Omicron and the original strains of the virus.
